CORONA Remedies Limited (CORONA) — FY26 Annual Report | 15 June 2026(2 announcements)

CORONA Remedies Limited announced that its 22nd Annual General Meeting will be held on July 9, 2026 at 11:00 A.M. IST via video conference, and shared the web link and path to access the Annual Report for FY 2025-26 on its website. The Board recommended a dividend of ₹10 per equity share of ₹10 each, subject to shareholder approval at the AGM. Shareholders are required to update KYC details and receive dividends electronically.

CORONA Remedies Limited reported FY2026 revenue of ₹1,403.18 crores, a 17.18% YoY increase, driven by strong growth in women's healthcare, cardio-diabetes, pain management, and urology segments. PAT grew 33.45% to [amount context mismatch] crores with a 14.20% margin, while ROCE stood at 40.79% and ROE at 29.16%. The company maintained its #27 position in IPM ranking, expanded its power brand portfolio to 8 (up from 3 in 2023), and achieved 34.80% covered market share. Strategic focus remains on chronic care, biosimilars, and international expansion, supported by EU-GMP and WHO-GMP certified facilities with 1.65 billion annual capacity. Key risks include brand concentration (76% revenue from 32 brands) and geographic dependency (45.20% from West Zone), though mitigated through product diversification and backward integration.